Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

VERTIS-CV: Ertugliflozin’s CV outcomes trial confirms SGLT2i benefits

Publish date:: June 18, 2020

Key clinical point: Results from the ertugliflozin cardiovascular outcomes trial showed general consistency with other drugs in its class.

Major finding: Ertugliflozin met its primary endpoint of noninferiority to placebo for major cardiovascular adverse events.

Study details: VERTIS-CV, a multicenter, international trial with 8,246 patients.

Disclosures: VERTIS-CV was sponsored by Merck and Pfizer, the companies that market ertugliflozin (Steglatro). Dr. Cannon has received research funding and fees from Merck and Pfizer and from several other companies.

Citation:

Cannon CP. ADA 2020.

This Week's Must Reads

Higher dose maximizes effects of magnesium sulfate for obese women,

Microplastics permeate human placentas,

One in five gestational carriers do not meet ASRM criteria,

Gender surgical outcomes differ following puberty suppression,

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Must Reads in Diabetes

Sac/val heart failure benefit extends to diabetes patients,

Don’t miss cardiovascular risk factors in transgender patients,

Semaglutide shows promise in NASH phase 2 study,

‘Modest’ benefit for post-MI T2D glucose monitoring,

Diabetic neuropathic pain linked to brain bioenergic anomalies,